Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
farletuzumab ecteribulin
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Farletuzumab ecteribulin is an investigational **folate receptor alpha-targeting antibody-drug conjugate** developed by Eisai. It comprises the humanized IgG1 anti-folate receptor alpha antibody farletuzumab conjugated through an enzymatically cleavable, cathepsin B-cleavable linker to the microtubule-dynamics inhibitor eribulin. Following binding to folate receptor alpha-positive tumor cells and internalization, linker cleavage releases eribulin, which disrupts microtubule dynamics and produces cytotoxic antitumor activity; released payload may also contribute to a bystander effect. The agent has been evaluated in ovarian, endometrial, non-small cell lung, primary peritoneal, fallopian tube, and triple-negative breast cancers. Eisai regained sole global development and commercialization rights after its collaboration with Bristol Myers Squibb ended on July 1, 2024. ([eisai.com](https://www.eisai.com/news/2024/news202448.html))
- Other names
- FZEC
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on farletuzumab ecteribulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on farletuzumab ecteribulin.